中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
11期
1346-1348
,共3页
肺肿瘤%临床分期%自噬蛋白%纤维蛋白原%D-二聚体%血小板
肺腫瘤%臨床分期%自噬蛋白%纖維蛋白原%D-二聚體%血小闆
폐종류%림상분기%자서단백%섬유단백원%D-이취체%혈소판
Lung cancer%Clinical stage%Autophagy protein%Fibrinogen%D-dimer%Platelet
目的 探讨肺癌患者自噬蛋白Beclin1、PLT、血浆D-二聚体、纤维蛋白原(Fib)含量变化,并观察其变化的趋势与肺癌临床分期、疗效和预后的关系.方法 采用流式细胞仪和全自动血凝仪以及全自动血细胞分析仪对50例不同病理分期的非小细胞肺癌患者和35例健康体检者(正常对照组)进行定量Beclin1和D-二聚体、血浆Fib水平和PLT检测.结果 与正常对照组比较,肺癌患者Beclin1蛋白的表达水平明显下降[(24.90±4.68)％比(92.27±4.52)％],Fib和D-二聚体水平明显升高,差异有统计学意义[(5.504±0.772) g/L比(2.953±0.719)g/L、( 1443.8±1664.5) μg/L比(148.8±82.4) μg/L,P＜0.01].肺癌组患者PLT计数为(506.60±65.21)×109/L,正常对照组为(210.94±47.34)×109/L,两者比较差异有统计学意义(P＜0.01).与正常对照组比较,随着病理恶性度的增加,肺癌组患者PLT明显增高,同时血浆Fib水平亦增高,差异有统计学意义(P＜0.01).结论 外周血PLT、血浆Fib和D-二聚体含量及自噬蛋白Beclin1的变化与肺癌的恶性度有明显相关性,联合多参数检测综合分析可作为临床疗效评估及判断预后的有效指标.
目的 探討肺癌患者自噬蛋白Beclin1、PLT、血漿D-二聚體、纖維蛋白原(Fib)含量變化,併觀察其變化的趨勢與肺癌臨床分期、療效和預後的關繫.方法 採用流式細胞儀和全自動血凝儀以及全自動血細胞分析儀對50例不同病理分期的非小細胞肺癌患者和35例健康體檢者(正常對照組)進行定量Beclin1和D-二聚體、血漿Fib水平和PLT檢測.結果 與正常對照組比較,肺癌患者Beclin1蛋白的錶達水平明顯下降[(24.90±4.68)％比(92.27±4.52)％],Fib和D-二聚體水平明顯升高,差異有統計學意義[(5.504±0.772) g/L比(2.953±0.719)g/L、( 1443.8±1664.5) μg/L比(148.8±82.4) μg/L,P＜0.01].肺癌組患者PLT計數為(506.60±65.21)×109/L,正常對照組為(210.94±47.34)×109/L,兩者比較差異有統計學意義(P＜0.01).與正常對照組比較,隨著病理噁性度的增加,肺癌組患者PLT明顯增高,同時血漿Fib水平亦增高,差異有統計學意義(P＜0.01).結論 外週血PLT、血漿Fib和D-二聚體含量及自噬蛋白Beclin1的變化與肺癌的噁性度有明顯相關性,聯閤多參數檢測綜閤分析可作為臨床療效評估及判斷預後的有效指標.
목적 탐토폐암환자자서단백Beclin1、PLT、혈장D-이취체、섬유단백원(Fib)함량변화,병관찰기변화적추세여폐암림상분기、료효화예후적관계.방법 채용류식세포의화전자동혈응의이급전자동혈세포분석의대50례불동병리분기적비소세포폐암환자화35례건강체검자(정상대조조)진행정량Beclin1화D-이취체、혈장Fib수평화PLT검측.결과 여정상대조조비교,폐암환자Beclin1단백적표체수평명현하강[(24.90±4.68)％비(92.27±4.52)％],Fib화D-이취체수평명현승고,차이유통계학의의[(5.504±0.772) g/L비(2.953±0.719)g/L、( 1443.8±1664.5) μg/L비(148.8±82.4) μg/L,P＜0.01].폐암조환자PLT계수위(506.60±65.21)×109/L,정상대조조위(210.94±47.34)×109/L,량자비교차이유통계학의의(P＜0.01).여정상대조조비교,수착병리악성도적증가,폐암조환자PLT명현증고,동시혈장Fib수평역증고,차이유통계학의의(P＜0.01).결론 외주혈PLT、혈장Fib화D-이취체함량급자서단백Beclin1적변화여폐암적악성도유명현상관성,연합다삼수검측종합분석가작위림상료효평고급판단예후적유효지표.
Objective To discuss the change of autophagy protein Beclinel,platelet(PLT),plasma D-dimer (D-D)and fibrinogen(Fib) in patients with lung cancer,and to observe the relationship of its change trend and lung cancer clinical stages,effect and prognosis.Methods Beclinel,D-D,plasma Fib level and PLT were quantitatively detected at different pathological staging of 50 cases non-small cell lung cancer patients and 35 cases healthy people.Results The decline of the expression of Beclinel protein in lung cancer patients than normal control group [(24.90 ± 4.68) ％ vs (92.27 ± 4.52 ) ％ ],and the Fib and D -dimer expression level changes significantly increased[(5.504 ±0.772) g/L vs (2.953 ±0.719)g/L,(1443.8 ± 1664.5) μg/L vs(148.8 ±82.4) μg/L,P ＜0.01 ].PLT count in lung cancer patients was (506.60 ±65.21 ) x 109/L,showing a statistically significant difference from normal group[(210.94 ±47.34) x 109/L](P ＜ 0.05 ).Compared with normal group,with pathological malignant degree inccreasing, patients' plasma PLT, Fib level increased significantly (P ＜ 0.01 ).Conclusion Peripheral blood plasma PLT,Fib and D-D levels and autophagy protein Beclinel are correlated to lung cancer malignant degree,which can be used as indexes of the clinical efficacy evaluation and prognosis.
